Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial
Journal of Thrombosis and Haemostasis · 2026-07 · 24 (7) · 2492-2505
DOI: 10.1016/j.jtha.2026.03.006 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-07. Verfasst von Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators und 59 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, University of Bristol, Bristol, UK. Electronic address: c.bradbury@bristol.ac.uk. Hauptthemen laut MEDLINE: Heparin, COVID-19, Anticoagulants, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University Health System, Health Research Board, Ministère des Solidarités et de la Santé.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
BACKGROUND: The optimal thromboprophylaxis among critically ill adults with COVID-19 is uncertain. OBJECTIVES: To determine the effectiveness and safety of intermediate-dose heparin compared with standard low-dose thromboprophylaxis. METHODS: In an ongoing adaptive platform trial (randomized embedded multifactorial adaptive platform for community-acquired pneumonia), critically ill patients with COVID-19 were randomized to intermediate-dose heparin or standard low-dose thromboprophylaxis. Interventions were continued in hospital for up to 14 days. The primary endpoint was organ support-free days (OSFDs), an ordinal outcome combining in-hospital survival and the number of days free of intensive care unit-based respiratory or cardiovascular organ support through 21 days. The primary analysis was an adjusted Bayesian hierarchical cumulative logistic model. An odds ratio (OR) > 1.0 represents an improved outcome with intermediate-dose heparin. RESULTS: Between April 27, 2021 and November 25, 2023, 1255 critically ill adults with COVID-19 were enrolled from 78 sites in 15 countries, of whom 1254 completed follow-up (n = 572 intermediate-dose, n = 682 low-dose). Enrollment was terminated prior to reaching a prespecified statistical trigger due to declining case numbers and slow recruitment. Median age was 59 years, and 36.7% were female (n = 461/1255). The probability that intermediate-dose heparin improved OSFDs was 73.5% (OR, 1.06; 95% credible interval, 0.87, 1.30), which did not meet the prespecified superiority threshold of 99%. Hospital survival was 77.1% (441/572) and 76.7% (523/682) in the intermediate- and low-dose heparin groups, respectively (median adjusted OR, 1.14; 95% credible interval, 0.86, 1.52). Major bleeding occurred in 10 of 572 (1.7%) and 14 of 682 (2.1%) patients receiving intermediate and standard low doses, respectively. CONCLUSION: Intermediate-dose heparin did not improve OSFDs or survival compared with standard thromboprophylaxis in critically ill patients with COVID-19. (ClinicalTrials.gov number: CT02735707).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health Sciences, University of Bristol, Bristol, UK. Electronic address: c.bradbury@bristol.ac.uk.
- University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Peter Munk Cardiac Centre at University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada.
- Université Versailles Saint-Quentin-en-Yvelines - Université Paris Saclay, Montigny-le-Bretonneux, France.
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Ara.
- Nepal Mediciti Hospital, Lalitpur, Nepal.
Förderung
- National University Health System
- Health Research Board
- Ministère des Solidarités et de la Santé
- Canadian Institutes of Health Research
- Ministry of Health -Singapore
- National Medical Research Council
- National Institute for Health and Care Research
- European Commission
Zitieren
APA
Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators, Bradbury, C. A., McVerry, B. J., Lawler, P. R., Angus, D. C., Annane, D., Arabi, Y. M., Aryal, D., Au, C., Beane, A., Berry, S. M., Berry, L. R., Best-Lane, J., Bihari, S., Bonten, M., Brunkhorst, F., Burrell, A., Buxton, M., Carrier, M., …, & Nichol, A. D. (2026). Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial. Journal of Thrombosis and Haemostasis, 24(7), 2492-2505. https://doi.org/10.1016/j.jtha.2026.03.006
Vancouver
Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators, Bradbury CA, McVerry BJ, Lawler PR, Angus DC, Annane D, et al. Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial. Journal of Thrombosis and Haemostasis. 2026;24(7):2492-2505. doi:10.1016/j.jtha.2026.03.006
BibTeX
@article{RandomizedEmbeddedMultifactorialAdaptivePlatformforCommunityacquiredPneumoniaREMAPCAPInvestigators2026,
author = {Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators, Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators and Bradbury, Charlotte A and McVerry, Bryan J and Lawler, Patrick R and Angus, Derek C and Annane, Djillali and Arabi, Yaseen M and Aryal, Diptesh and Au, Carly and Beane, Abigail and Berry, Scott M and Berry, Lindsay R and Best-Lane, Janis and Bihari, Shailesh and Bonten, Marc and Brunkhorst, Frank and Burrell, Aidan and Buxton, Meredith and Carrier, Marc and Cecconi, Maurizio and Cheng, Allen C and Cove, Matthew and Derde, Lennie P G and Detry, Michelle A and Estcourt, Lise J and Fergusson, Dean A and Fitzgerald, Mark and Fowler, Rob A and Goligher, Ewan C and Green, Cameron and Haniffa, Rashan and Harrison, David A and Hays, Leanne M C and Higgins, Alisa M and Hills, Thomas and Horvat, Christopher M and Huang, David T and Hunt, Beverley J and Ichihara, Nao and Jayakumar, Devachandran and Keattch, Stephanie and Kumar, Anand and Laffan, Michael A and Lamontagne, Francois and Leeper, Christine M and Lewis, Roger J and Lorenzi, Elizabeth and Lother, Sylvain A and Marshall, John C and McArthur, Colin J and McAuley, Daniel F and McGlothlin, Anna and McGuinness, Shay P and McQuilten, Zoe K and Middeldorp, Saskia and Morpeth, Susan and Mouncey, Paul R and Murthy, Srinivas and Neal, Matthew D and Nichol, Alistair D},
title = {Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {7},
pages = {2492--2505},
doi = {10.1016/j.jtha.2026.03.006}
}
EUVIMED